Journal of Craniofacial Surgery · 2017 · 18 citations · 8 references
MedicineSurgeryInterventional RadiologyMicrosurgeryVascular SurgeryLymphatic AnatomyLymphatic MalformationsVascular MalformationsCongenital Lymphatic MalformationsFluoroscopic GuidanceLymphatic ArchitectureLymphatic Malformation SclerotherapyMixed Lymphatic MalformationsNeck Lymphatic MalformationsPediatric Vascular AnomaliesRetrospective Record Review
PURPOSE: Herein, the authors aim to describe their findings of novel architectural types of lymphatic malformations (LM) and explain the relationship between these architectures and OK-432 treatment outcomes. METHODS: A retrospective review was conducted of all patients diagnosed with a LM treated with OK-432 at the Vascular Anomalies Clinic at BC Children's Hospital from December 2002 to January 2012. RESULTS: Twenty-seven patients were included in the study. Sixty percent of lesions were present by 2 years of age with the majority located in the head and neck (59%). The average number of sclerotherapy procedures was 1.4 per patient. Treatment under fluoroscopic guidance revealed 3 new LM architectures: open-cell microcystic, closed-cell microcystic, and lymphatic channel. Response to treatment was complete or good for 14/19 macrocystic and for 1/2 mixed lesions. Open-cell microcystic LMs gave a complete or good response for 3/3, which was attributed to OK-432 freely communicating between cysts. Closed-cell microcystic LM had localized cysts that did not allow OK-432 to freely communicate and were associated with partial responses, 2/2. The lymphatic channel had a partial response. There were 2 minor complications and 1 instance of recurrence. CONCLUSIONS: The identification of 3 new LM architectures expands the current accepted classification to include: open-cell microcystic, closed-cell microcystic, and lymphatic channels. The majority of complete responses to OK-432 were found with macrocystic lesions. Open-cell microcystic lesions respond better to OK-432 than closed-cell microcystic lesions, and lymphatic channels may respond to OK-432. These key architecture-response relationships have direct clinical implications for treatment with OK-432 sclerotherapy.
8
25 Years' experience with lymphangiomas in children
Aayed Alqahtani, L.T. Nguyen, Hélène Flageole et al. · Journal of Pediatric Surgery · 1999 · 430 citations
Medicine, Pathology, Pediatrics +5
Cystic Hygroma/Lymphangioma: A Rational Approach to Management
Thomas L. Kennedy, Mark Whitaker, Phillip Pellitteri et al. · The Laryngoscope · 2001 · 271 citations · Full text
Medicine, Neck Surgery, Surgery +7
OK-432 Therapy for Lymphangiomas
Richard J. Smith, Diane K. Burke, Yutaka Satō et al. · Archives of Otolaryngology - Head and Neck Surgery · 1996 · 120 citations
Treatment of Lymphangiomas in Children: An Update of Picibanil (OK‐432) Sclerotherapy
John H. Greinwald, Diane K. Burke, Rolland I. Poust et al. · Otolaryngology · 1999 · 115 citations · Full text
Pharmacy, Child Health, Pediatrics +10